CN Patent

CN110691779B — 治疗血液系统恶性肿瘤和尤因肉瘤的方法

Assigned to Kura Oncology Inc · Expires 2023-10-10 · 3y expired

What this patent protects

本公开提供了使用多发性内分泌抑癌蛋白抑制剂治疗血液系统恶性肿瘤和尤因肉瘤的方法。还提供了用于这些方法的组合物。

USPTO Abstract

本公开提供了使用多发性内分泌抑癌蛋白抑制剂治疗血液系统恶性肿瘤和尤因肉瘤的方法。还提供了用于这些方法的组合物。

Drugs covered by this patent

revumenib-citrate (REVUMENIB CITRATE)

Patent Metadata

Patent number: CN110691779B
Jurisdiction: CN
Classification: —
Expires: 2023-10-10
Drug substance claim: No
Drug product claim: No
Assignee: Kura Oncology Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.